Sarah Mennenga

Dr. Sarah Mennenga has over 15 years of experience in behavioral neuroscience research, and 7+ years of experience studying the effects of psilocybin-assisted psychotherapy in clinical populations, including people with mood, anxiety, and substance use disorders. Under the mentorship of Drs. Michael Bogenschutz and Stephen Ross at the NYU Langone Center for Psychedelic Medicine, Dr. Mennenga had a unique opportunity to contribute to some of the first modern clinical trials of psilocybin-assisted psychotherapy for addiction and cancer-associated anxiety and depression. Results from these and a handful of other trials established the safety and potential effectiveness of psilocybin treatment in psychiatry, and paved the way for all modern clinical psychedelic research. Dr. Mennenga has authored 10+ peer-reviewed manuscripts on psychedelic-assisted psychotherapy, and is among a handful of experts in the implementation of clinical trials with schedule I drugs in the United States. Dr. Mennenga is also an expert in neuroendocrinology and the neurobiology of addiction, as well as cross-species translation. Her work in these domains explores how different hormonal states affect the etiology and treatment of mental health disorders, and translation of neurobiological and behavioral endpoints from rodent to human clinical research (and vice versa).